- Doctors treat mycobacterium avium complex (MAC) disease, the most common NTM lung infection, with a combination of three antibiotics: Either azithromycin (Zithromax) and clarithromycin (Biaxin).
- Jun 29, 2019 doctors treat mycobacterium avium complex (mac) disease, the most common ntm lung infection, with a combination of three antibiotics:.either azithromycin and clarithromycin.ethambutol.rifampin.
The “Hesitation Blues” is a traditional blues/folk tune that was first recorded a century ago. Since that time, more than 40 artists with diverse musical pedigrees have recorded the song, ranging from Lead Belly to Doc and Merle Watson to Hot Tuna. An interesting aspect of the various recordings is that while the narrative of the song consistently expresses carnal frustration, the actual.
Shannon Kasperbauer, MDShannon Kasperbauer, MD
- Associate Professor of Medicine
- National Jewish Health
Charles L Daley, MD
- Professor of Medicine
- National Jewish Health
C Fordham von Reyn, MD
- Section Editor — Tuberculosis; Nontuberculous Mycobacterial Infections
- Professor of Medicine
- Geisel School of Medicine at Dartmouth
Mac Lung Disease Survival Rate
Allyson Bloom, MD
- Director, Editorial Training — UpToDate
- Senior Deputy Editor — UpToDate
- Deputy Editor — Infectious Diseases
- Clinical Instructor in Medicine
- Harvard Medical School
INTRODUCTION
Treatment of nontuberculous mycobacterial (NTM) infection of the lung is dependent upon a number of factors, including the species of the infecting organism. Members of Mycobacterium avium complex (MAC) are the most common pulmonary NTM pathogens in almost all regions of the world. The three predominate species to cause human disease among the twelve species within the complex are Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium chimaera [1,2].
The treatment of MAC pulmonary infections will be reviewed here. The management of pulmonary disease caused by other slow-growing NTM, such as Mycobacterium kansasii, Mycobacterium malmoense, and Mycobacterium xenopi,and by rapidly growing mycobacterium, such as Mycobacterium abscessus, Mycobacterium fortuitum complex, and Mycobacterium chelonae, is discussed separately. (See 'Treatment of lung infection with Mycobacterium kansasii and other less common nontuberculous mycobacteria in adults' and 'Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum'.)
The epidemiology, microbiology, clinical manifestations, and diagnosis of NTM infection are also discussed elsewhere. (See 'Overview of nontuberculous mycobacterial infections in HIV-negative patients' and 'Epidemiology of nontuberculous mycobacterial infections' and 'Diagnosis of nontuberculous mycobacterial infections of the lungs'.)
NTM pulmonary infection in patients with cystic fibrosis is also discussed elsewhere. (See 'Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection', section on 'Nontuberculous mycobacteria'.)
CATEGORIES OF DISEASE
In general, antimycobacterial treatment of MAC should only be considered in patients who meet the clinical, radiographic, and microbiologic criteria for the diagnosis of nontuberculous mycobacterial (NTM) infection (table 1) [3]. (See 'Diagnosis of nontuberculous mycobacterial infections of the lungs'.)
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
Subscribers log in here
Literature review current through: Sep 2020. | This topic last updated: Sep 25, 2020.
The content on the UpToDate website is not intended nor recommended as a substitutefor medical advice, diagnosis, or treatment. Always seek the advice of your own physician orother qualified health care professional regarding any medical questions or conditions. Theuse of this website is governed by the UpToDate Terms of Use©2020 UpToDate, Inc.
Mac Lung Infection
- Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardia spp, and other aerobic actinomyces. 3rd ed. M24. Clinical and Laboratory Standards Institute. Wayne, PA 2018.
- Clinical and Laboratory Standards Institute. Performance standards for susceptibility testing of mycobacteria, nocardia spp, and other aerobic actinomyces. 1st ed. M62. Clinical and Laboratory Standards Institute. Wayne, PA 2018.